Safety profile of methotrexate in inflammatory bowel disease

References

• Rang HP, Dale MM, Ritter JM, et al. Pharmacology. 5th ed. Edinburgh: Churchill Livingstone; 2003.
   Google Scholar
• Klippel JH, Decker JL. Methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312:853–854.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312:818–822.
   PubMed Web of Science ®Google Scholar
• Black RL, O’Brien WM, Van Scott EJ, et al. Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. Jama. 1964;189:743–747.
   PubMed Web of Science ®Google Scholar
• Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984;27:376–381.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332:292–299.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med. 2000;342:1627–1632.
   PubMed Web of Science ®Google Scholar
• Al-Awadhi A, Dale P, McKendry RJR. Pancytopenia associated with low dose methotrexate therapy: a regional survey. J Rheumatol. 1993;20:1121–1125.
   PubMed Web of Science ®Google Scholar
• Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors: four case reports and a review of the literature. J Rheumatol. 1987;14:1164–1171.
   PubMed Web of Science ®Google Scholar
• Jolivet J, Cowan KH, Curt GA, et al. The pharmacology and clinical use of methotrexate. N Engl J Med. 1983;309:1094–1104.
   PubMed Web of Science ®Google Scholar
• Cronstein BN. Molecular mechanism of methotrexate action in inflammation. Inflammation. 1992;16:411–423.
   PubMed Web of Science ®Google Scholar
• Eliakim R, Karmeli F, Chorev M, et al. Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis. Scand J Gastroenterol. 1992;27:968–972.
   PubMed Web of Science ®Google Scholar
• Egan LJ, Sandbourne WJ. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo ClinProc. 1996;71:69e80.
   Web of Science ®Google Scholar
• Arora S, Katkov WN, Cooley J, et al. A double-blind, randomized, placebo-controlled trial of methotrexate in Crohn’s disease [abstract]. Gastroenterology. 1992;102:A591.
   Google Scholar
• McDonald JWD, Wang Y, Tsoulis DJ, et al. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD003459.
   Web of Science ®Google Scholar
• Lémann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn’s disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000;95:1730–1734.
   PubMed Web of Science ®Google Scholar
• Mañosa M, García V, Castro L, et al. Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy. J Crohns Colitis. 2011;5:397–401.
   PubMed Web of Science ®Google Scholar
• Seinen ML, Ponsioen CY, De Boer NK, et al. Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn’s disease. ClinGastroenterolHepatol. 2013;11(6):667–672.
   Web of Science ®Google Scholar
• Feagan BG, McDonald JWD, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146:681–688.
   PubMed Web of Science ®Google Scholar
• Fraser AG. Methotrexate: first or second-line immunomodulator? Eur J Gastroenterol Hepatol. 2003;15:225–231.
   PubMed Web of Science ®Google Scholar
• Annese V, Beaugerie L, Egan L, et al., ECCO. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015 Nov;9(11):945–965.
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011 Jan;9(1):36–4.
   PubMed Web of Science ®Google Scholar
• Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110:353–356.
   PubMed Web of Science ®Google Scholar
• Wahed M, Louis-Auguste JR, Baxter LM, et al. Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. AlimPharmacolTher. 2009;30(6):614–620.
   Web of Science ®Google Scholar
• Parker R, Dixit A, Fraser A, et al. Clinical experience of methotrexate in Crohn’s disease: response, safety and monitoring of treatment. Postgrad Med J. 2010;86(1014):208–211.
   PubMed Web of Science ®Google Scholar
• Saibeni S, Bollani S, Losco A, et al. The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. Dig Liver Dis. 2012;44(2):123–127.
   PubMedGoogle Scholar
• Carbonnel F, Colombel JF, Filippi J, et al. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016 Feb;150(2):380–388.e4.
   PubMed Web of Science ®Google Scholar
• Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology. 1996;110:1416–1421.
   PubMed Web of Science ®Google Scholar
• Mate-Jimenez J, Hermida C, Cantero-Perona J, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J GastroenterolHepatol. 2000;12:1227–1233.
   PubMed Web of Science ®Google Scholar
• Cummings JR, Herrlinger KR, Travis SP, et al. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther. 2005;21(4):385–389.
   PubMed Web of Science ®Google Scholar
• Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment PharmacolTher. 2002;16(10):1751–1759.
   PubMed Web of Science ®Google Scholar
• Wang Y, MacDonald JK, Vandermeer B, et al. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015 Aug 11;8:CD007560.
   PubMed Web of Science ®Google Scholar
• Chande N, Wang Y, MacDonald JK, et al. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014 Aug 27;8:CD006618.
   PubMed Web of Science ®Google Scholar
• Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20:1845–1849.
   PubMed Web of Science ®Google Scholar
• Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn’s disease. Aliment PharmacolTher. 2003;18:57–63.
   PubMed Web of Science ®Google Scholar
• Fallingborg J, Pedersen P, Jacobsen BA. Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn’s disease. Dig Dis Sci. 1998;43:702–705.
   PubMed Web of Science ®Google Scholar
• Rana SV, Sharma S, Malik A, et al. Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease. Dig Dis Sci. 2013;58:2594–2598.
   PubMed Web of Science ®Google Scholar
• Hamilton RA, Kremer JM. Why intramuscular dosing may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol. 1997;36:86–90.
   PubMedGoogle Scholar
• Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2005;(1):CD003459. [PubMed: 15674908]
   PubMed Web of Science ®Google Scholar
• Turner D, Doveh E, Cohen A, et al. Efficacy of oral methotrexate in paediatric Crohn’s disease: a multicentre propensity score study. Gut. 2015 Dec;64(12):1898–1904.
   PubMed Web of Science ®Google Scholar
• Kozlowski RD, Steinbrunner JV, MacKenzie AH, et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990;88:589–592.
   PubMed Web of Science ®Google Scholar
• Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis ClinNorth Am. 1994;20(2):513–528. [PubMed: 8016424]
   PubMed Web of Science ®Google Scholar
• Salach RH, Cash JM. Methotrexate: the emerging drug of choice for serious rheumatoid arthritis. ClinTher. 1994;16:912–922.
   Google Scholar
• Filer A, Freeguard J, Rowe I. Letter to the Editor. Rheumatology. 2003;42:397e8.
   Web of Science ®Google Scholar
• Baron SE, Wilson C. A Yorkshire regional audit on methotrexate monitoring. Br J Dermatol. 2003;149(Suppl):19.P-1.
   Google Scholar
• Martin LA, Blackford S. Regional audit of methotrexate prescribing and monitoring. Br J Dermatol. 2005;153(Suppl 1):32. P-38.
   PubMed Web of Science ®Google Scholar
• Carter MJ, Lobo AJ, Travis SPL, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(SupplV):v1e16.
   Google Scholar
• Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004;43:267–271.
   PubMed Web of Science ®Google Scholar
• Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013 Dec;145(6):1459–1463.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar;130(3):940–987.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis. 2014;8:443–468.
   Google Scholar
• Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1993;36(6):795–803.
   PubMed Web of Science ®Google Scholar
• Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994;121(11):833–841. [PubMed: 7978695]
   PubMed Web of Science ®Google Scholar
• Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349:658–665.
   PubMed Web of Science ®Google Scholar
• Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011;365:1586–1596.
   PubMed Web of Science ®Google Scholar
• Shea B, Swinden MV, TanjongGhogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013 May 31;5:CD000951.
   PubMed Web of Science ®Google Scholar
• Bridges SL, Alarcon JM, Koopman WJ. Methotrexate-induced liver abnormalities in rheumatoid arthritis. J Rheumatology. 1989;16:1180–1183.
   PubMed Web of Science ®Google Scholar
• Te HS, Schiano TD, Fan Kuan S, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95:3150–3156.
   PubMed Web of Science ®Google Scholar
• Van Swelm RP, Laarakkers CM, Kooijmans-Otero M, et al. Biomarkers for methotrexate-inducedliver injury: urinary protein profiling of psoriasis patients. Toxicol Lett. 2013;221(3):219–224.
   PubMed Web of Science ®Google Scholar
• Berends MA, Snoek J, De Jong EM, et al. Liver injury in long-term methotrexate treatment inpsoriasis is relatively infrequent. AlimPharmacolTher. 2006;24(5):805–811.
   Web of Science ®Google Scholar
• Fournier MR, Klein J, Minuk GY, et al. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol. 2010;105(7):1620–1626.
   PubMed Web of Science ®Google Scholar
• Khan N, Abbas AM, Whang N, et al. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis. 2012 Feb;18(2):359–367.
   PubMed Web of Science ®Google Scholar
• Valentino PL, Church PC, Shah PS, et al. Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014 Jan;20(1):47–59.
   PubMed Web of Science ®Google Scholar
• Roenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am AcadDermatol. 1998;38(3):478–485.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum. 1994;37:316–328.
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay JO, et al., European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010 Feb; 4(1):28–62.
   PubMed Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526.
   PubMed Web of Science ®Google Scholar
• Imbert-Bismut F, Ratziu V, Pieroni L, et al., MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069–1075.
   PubMed Web of Science ®Google Scholar
• De Le´dinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis andcirrhosis by transient elastography(FibroScan) in HIV-HCV co-infectedpatients. J AcquirImmuneDeficSyndr. 2006 Feb 1;41(2):175–179.
   Google Scholar
• Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55:403–408.
   PubMed Web of Science ®Google Scholar
• Ziol M, Handra-Luca A, Kettaneh A, et al. Non-invasive assessment of liver fibrosis by stiffness measurement: a prospective multicenter study in patients with chronic hepatitis C. Hepatology. 2005;41:48–54.
   PubMed Web of Science ®Google Scholar
• Barbero-Villares A, Mendoza Jiménez-Ridruejo J, Taxonera C, et al., Madrid Group for the Study of Inflammatory Bowel Disease ENICMAD. Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol. 2012 May; 47(5):575–579.
   PubMed Web of Science ®Google Scholar
• Laharie D, Zerbib F, Adhoute X, et al. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn’s disease patients treated with methotrexate. Aliment PharmacolTher. 2006 Jun 1;23(11):1621–1628.
   PubMed Web of Science ®Google Scholar
• Salliot C, Van Der Heijde D. Long-term safety of methotrexate monotherapy inpatients with rheumatoid arthritis: a systematic literature research. Ann RheumDis. 2009 Jul;68(7):1100–1104.
   PubMed Web of Science ®Google Scholar
• Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014 Jun;10(6):CD000957.
   Google Scholar
• Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929–936.
   PubMed Web of Science ®Google Scholar
• Afzali A, Park CJ, Zhu K, et al. preoperative use of methotrexate and the risk of early postoperative complications in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;8:1887–1895.
   Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–1422.
   PubMed Web of Science ®Google Scholar
• Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology. 2004;43:143–147.
   PubMed Web of Science ®Google Scholar
• Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease: cytotoxic drugs. Part 1. Am Rev Respir Dis. 1986;133:321–340.
   PubMed Web of Science ®Google Scholar
• Brechmann T, Heyer C, Schmiegel W. Methotrexate-induced pneumonitis in a woman with Crohn’s disease. Dtsch Med Wochenschr. 2007;132:1759–1762.
   PubMed Web of Science ®Google Scholar
• Margagnoni G, Papi V, Aratari A, et al. Methotrexate-induced pneumonitis in a patient with Crohn’s disease. J Crohn’s Colitis. 2010;4(2):211–214.
   Google Scholar
• Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case–control study. Ann Intern Med. 1997;127:356–364.
   PubMed Web of Science ®Google Scholar
• Golden MR, Katz RS, Balk RA, et al. The relationship of pre-existing lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis.J. Rheumatol. 1995;22:1043–1047.
   Web of Science ®Google Scholar
• Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. EurRespir J. 2000;15(2):373–381.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Alarcon GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 1997;40(10):1829–1837.
   PubMed Web of Science ®Google Scholar
• Balk RA. Methotrexate-induced lung injury. Uptodate Online. 2009;17:2–9.
   Google Scholar
• Johns DG, Rutherford LD, Leighton PC, et al. Secretion of methotrexate into human milk. Am J Obstet Gynecol. 1972;112(7):978–980.
   PubMed Web of Science ®Google Scholar
• Van Der Woude CJ, Ardizzone S, Bengtson MB, et al., European Crohn’s and Colitis Organization. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015 Feb;9(2):107–24. Review.
   PubMed Web of Science ®Google Scholar
• Dara P, Slater LM, Armentrout SA. Successful pregnancy during chemotherapy for acute leukemia. Cancer. 1981;47:845–846.
   PubMed Web of Science ®Google Scholar
• Hyoun SC, Obican SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A ClinMolTeratol. 2012;94(4):187–207.
   PubMed Web of Science ®Google Scholar
• Buckley LM, Bullaboy CA, Leichtman L, et al. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum. 1997;40(5):971–973.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, et al. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology (Oxford). 2014;53:757–763.
   PubMed Web of Science ®Google Scholar
• Sands K, Jansen R, Zaslau S, et al. Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. Aliment PharmacolTher. 2015;41:821–834.
   PubMed Web of Science ®Google Scholar
• Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008;59:794–799.
   PubMed Web of Science ®Google Scholar
• Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002;99:3909–3915.
   PubMed Web of Science ®Google Scholar
• Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol. 2010;37:2205–2215.
   PubMed Web of Science ®Google Scholar
• Masunaga Y, Ohno K, Ogawa R, et al. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007 Jan;41(1):21–28.
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000 Oct;47(4):514–519.
   PubMed Web of Science ®Google Scholar
• Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009;58:1427–1436.
   PubMed Web of Science ®Google Scholar
• Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-a antagonists and risk of cancer in patients with inflammatory bowel disease. Jama. 2014;311:2406–2413.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Sandborn WJ, Colombel J-F, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014;146:941–949.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–1625.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Cesame Study Group. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;14:1621–1628.
   Web of Science ®Google Scholar
• Lopez A, Mounier M, Bouvier AM, et al.; CESAME Study Group. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:1324–1329.
   PubMed Web of Science ®Google Scholar
• Lim AY, Gaffney K, Scott DG. Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford). 2005;44:1051–1055.
   PubMed Web of Science ®Google Scholar
• De Rotte MC, Den Boer E, De Jong PH, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:408–414.
   PubMed Web of Science ®Google Scholar
• Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2010 Jun;16(6):CD000545.
   Google Scholar
• Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn’s disease: a randomised, investigator-blind study. Dig Liver Dis. 2003;35:619–627.
   PubMedGoogle Scholar
• Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn’s disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol. 1997;92(12):2203–2209.
   PubMed Web of Science ®Google Scholar